MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: GenScript Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GenScript to Launch New Platform to Save up to A Billion USD for Worldwide Research Community - GenScript, the world’s leading gene synthesis provider, is to test launch its new open-access plasmid platform, namely MolecularCloud™, today - GenScript.com
GenScript to Launch New Platform to Save up to A Billion USD for Worldwide Research Community

 

NewswireToday - /newswire/ - Piscataway, NJ, United States, 2018/07/09 - GenScript, the world’s leading gene synthesis provider, is to test launch its new open-access plasmid platform, namely MolecularCloud™, today - GenScript.com. 1548:HK

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The free platform aims to accelerate innovation in biology by promoting sharing of wisdom and supporting conversation among researchers.

"Today we reached an important milestone on our way to revolutionize how research is done," said Eric Wang, VP of Marketing at GenScript. The new platform originates from a popular service offered by GenScript since 2015, known as CloneArk™. This free service allows clients to archive clones from past orders at GenScript for future reuse. Three years into its launch, there are about one million clones in CloneArk™ system with deposits growing fast every day.

"There are many benefits to use CloneArk," explained Dr. Lihua Zhang, senior product manager in charge of MolecularCloud project at GenScript. "For example, a researcher may repeatedly need the same piece of sequence during his/her project. For a 1500 bp gene, the cost of de novo synthesis is about $525 while CloneArk™-based synthesis would only cost about $125; up to $300 saving per clone, not to mention the time saved in the process." According to Zhang, in 2018 requests for CloneArk-based synthesis will reach 45,000, indicating that GenScript will save as much as $13M in funding for the global research community.

Before 2017 technical support at GenScript manually designed the right cloning strategy by blasting against client’s CloneArk™ database for selected customers. With the increase in CloneArk™ usage, GenScript developed GenSmart™ Ordering System, the first AI-assisted ordering system to make sure everyone enjoys the savings. This ordering system automatically analyzes target sequences not only against previously-synthesized genes for the same client, but also in GenScript’s ORF clone collection to find the most time and cost efficient route for creating desired DNA constructs. In addition, GenSmart™ automatically detects and reports common errors in the design, including frame shifts, pre-mature stop codons or insert direction issues in most commercial vectors. "GenSmart™ will save over $150M for the global research community, if researchers adopt and use it correctly," claimed Dr. Zhang.

In 2018, the team took one step further to launch MolecularCloud™, which allows reuse of clones made by other scientists who have decided to share their constructs in this public platform. "We realized that there are still many scientists constructing clones in their lab although someone else had already published the same clone. This is not efficient. Obviously, CloneArk™ is not enough because it only provides access to reuse your own clones. So we decided to do something," said Wang. "We designed a free platform for the community to share plasmids, which are then searchable through GenSmart™ and can be reused conveniently by everyone."

Besides serving as a plasmid repository, MolecularCloud™ comes with everything featured by an internet platform. "For example, you can search, favorite and comment on any plasmid, making it a perfect platform to explore and exchange research ideas," explained Wang. "Our goal is to bring in the power of internet to support conversation and sharing of wisdom among researchers, because the more we bring great minds together, the faster innovation can happen."

Among the many benefits of MolecularCloud™, cost and time savings are the top attractions. According to the estimate of Dr. Zhang‘s team, this open platform would save up to a billion USD per year for labs all over the world. This is in addition to the significant savings in time and effort involved in searching and requesting plasmids through traditional ways. "Plasmid is one of the most important reagents in biology research," said Wang. "Many experiments in research begin with plasmids. They are not only nucleotides, but also carry design and wisdom with them. Our platform is going to give your plasmids the attention they deserve." With researchers across the globe depositing their plasmids into MolecularCloud™ with proper MTA, everyone can take full advantage of these plasmids and the hidden wisdom within them to advance science.

About GenScript

GenScript (genscript.com) is a leading contract research organization providing gene, peptide, protein, CRISPR, and antibody reagents to scientists in over 100 countries worldwide. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early stage pharmaceutical development. With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents in order to Make Research Easy for all scientists.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GenScript Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenScript to Launch New Platform to Save up to A Billion USD for Worldwide Research Community

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sally Wang - GenScript.com 
732-885-9188 x111 sally.wang[.]genscript.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GenScript Corporation / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow, Inc.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)